Form 4: Athira Pharma Director John M. Fluke Jr. Acquires Stock Options

Director John M. Fluke Jr. of Athira Pharma, Inc. acquired stock options on May 24, 2024, as reported in a Form 4 filing with the SEC.

Summary

• John M. Fluke Jr., a director of Athira Pharma, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 24, 2024.
• Fluke acquired 20,900 stock options with an exercise price of $2.64.
• These options vest on the earlier of May 24, 2025, or the day before the next annual meeting after May 24, 2024.
• The options expire on May 23, 2034.
• Following the transaction, Fluke directly owns 20,900 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The acquisition of options by a director is generally viewed as a slightly positive signal, but without further context, it's difficult to assess the overall impact.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. They provide transparency into insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates